Elegen
Elegen is a synthetic biology company that has developed the world's only entirely cell-free platform for rapid, high-quality DNA production, using microfluidics, AI, and robotics to deliver long, clonal-quality, high-complexity DNA products with unprecedented speed, low costs, and efficiency. The company's patented ENFINIA DNA platform eliminates the need for cells, cloning, and foundries, producing NGS-verified…
Funding snapshot
About
Elegen is a synthetic biology company that has developed the world's only entirely cell-free platform for rapid, high-quality DNA production, using microfluidics, AI, and robotics to deliver long, clonal-quality, high-complexity DNA products with unprecedented speed, low costs, and efficiency. The company's patented ENFINIA DNA platform eliminates the need for cells, cloning, and foundries, producing NGS-verified linear DNA with 99.999% per base accuracy (1:70,000 bp error rate) in 6-8 business days, up to 7 kb in length, ready for immediate use without cloning. The product portfolio includes ENFINIA Linear DNA, which arrives NGS-verified and ready to use without colony screening or additional sequencing, and ENFINIA IVT Ready DNA, designed for mRNA therapeutics development with encoded poly(A) tails delivered up to three times faster and free from bioburden, endotoxins, and recombination-mediated variation. Elegen's Gen II Cell Free Platform incorporates the world's first directed split-pool microfluidic synthesizer combined with patented cell-free cloning technology, fully automating production of long, clonal-quality, high-complexity double-stranded DNA. The platform serves applications in cell and gene therapy, genome editing, mRNA prophylactic vaccines, mRNA personalized cancer vaccines, and protein expression, with pricing as low as $0.07 per base pair. Founded in 2017 and headquartered in San Carlos, California, Elegen has raised $35.0M in Series B funding from investors including Triatomic, GSK, Andreessen Horowitz, KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures, Agilent, HHS, and Sahsen Ventures.
Business model
Genomics > Applied Genomics > Synthetic Biology
Team background
College Wise > Stanford University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.